EMA and FDA green-light MoonLake to advance IL-17 inhibitorIL-17 inhibitor

28 Feb 2024
www.pharmaceutical-technology.com
Phase 2Phase 3Clinical ResultImmunotherapyDrug Approval
EMA and FDA green-light MoonLake to advance IL-17 inhibitor
Preview
Source: Pharmaceutical Technology
Hidradenitis suppurativa causes painful lumps and abscesses in areas where skin rubs together, like the armpits and groin. Credit: iced.espresso via Shutterstock.
MoonLake Immunotherapeutics will advance its IL-17 inhibitorIL-17 inhibitor into a Phase III programme following positive feedback from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The trivalent camelid nanobody, called sonelokimab (M-1095), is indicated for the treatment of hidradenitis suppurativa – a chronic skin condition causing painful lumps and abscesses in areas where skin rubs together, like the armpits and groin.
The Phase III VELA programme will evaluate sonelokimab’s effectiveness by comparing a single 120mg dose of the nanobody to placebo over 16 weeks. After this period, the placebo group will switch to sonelokimab. The trial will run for 52 weeks followed by an open-label extension study. The primary endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) 75, measures a ≥75% reduction in abscesses and inflammatory nodules without an increase in abscess or draining tunnel count against the baseline.
The trial, enrolling 800 patients, aims to support a biologics license application and an EU marketing authorisation application, according to MoonLake.
IL-17 inhibitorsIL-17 inhibitors are drugs that are designed to specifically target immune cells. IL-17 is proven to be implicated in inflammatory autoimmune conditions. In October 2023, the FDA approved the first IL-17A and IL-17F inhibitorIL-17F inhibitor for patients with moderate to severe plaque psoriasis, UCB’s BIMZELX (bimekizumab).
See Also:Minerva hit with FDA rejection for schizophrenia symptom drug
EMA and FDA green-light MoonLake to advance IL-17 inhibitor
Preview
Source: Pharmaceutical Technology
FDA approves Allecra’s EXBLIFEP for cUTI treatment
EMA and FDA green-light MoonLake to advance IL-17 inhibitor
Preview
Source: Pharmaceutical Technology
In June 2023, MoonLake released topline data from its Phase II MIRA trial (NCT05322473), revealing that 46% of patients receiving the 60 mg dose and 47% of those on the 120 mg dose achieved a 50% or greater reduction in disease activity symptoms by week 12, hitting the trial’s primary endpoint.
MoonLake is also investigating the candidate in trials for psoriatic arthritis, and plans to initiate Phase III trials in April 2024, following an end-of-Phase II meeting with the FDA scheduled for Q2 2024.
According to GlobalData’s Pharma Intelligence Center, a sales consensus forecasts sonelokimab to have global sales of $949m by 2029.
GlobalData is the parent company of Pharmaceutical Technology.
In the announcement about the regulators’ decisions, CEO of MoonLake Jorge Santos da Silva said: “The favourable response from both the FDA and EMA aligns with the strengths we have consistently highlighted in our trial programs and outlines a clear regulatory path for sonelokimab in hidradenitis suppurativa.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.